Background: HER2 is an established therapeutic target in breast and gastric cancers. The role of HER2 in rectal cancer is unclear, as conflicting data on the prevalence of HER2 expression in this disease have been reported. We evaluated the prevalence of HER2 and its impact on the outcome of high-risk rectal cancer patients treated with neoadjuvant CAPOX and CRT±cetuximab in the EXPERT-C trial. Patients and methods: Eligible patients with available tumour tissue for HER2 analysis were included. HER2 expression was determined by immunohistochemistry (IHC) in pre-treatment biopsies and/or surgical specimens (score 0-3+). Immunostaining was scored according to the consensus panel recommendations on HER2 scoring for gastric cancer. Tumours with equivocal IHC result (2+) were tested for HER2 amplification by D-ISH. Tumours with IHC 3+ or D-ISH ratio ≥2.0 were classified as HER2+. The impact of HER2 on primary and secondary end points of the study was analysed.
HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab Patients and methods: Eligible patients with available tumour tissue for HER2 analysis were included. HER2 expression was determined by immunohistochemistry (IHC) in pre-treatment biopsies and/or surgical specimens (score 0-3+). Immunostaining was scored according to the consensus panel recommendations on HER2 scoring for gastric cancer. Tumours with equivocal IHC result (2+) were tested for HER2 amplification by D-ISH. Tumours with IHC 3+ or D-ISH ratio ≥2.0 were classified as HER2+. The impact of HER2 on primary and secondary end points of the study was analysed.
Results: Of 164 eligible study patients, 104 (63%) biopsy and 114 (69%) surgical specimens were available for analysis.
Only 3 of 104 (2.9%) and 3 of 114 (2.6%) were HER2+, respectively. In 77 patients with paired specimens, concordance for HER2 status was found in 74 (96%). Overall, 141 patients were assessable for HER2 and 6 out of 141 (4.3%) had HER2 overexpression and/or amplification. The median follow-up was 58.6 months. HER2 was not associated with a difference in the outcome for any of the study end points, including in the subset of 90 KRAS/BRAF wild-type patients treated ±cetuximab.
Conclusions: Based on the low prevalence of expression as recorded in the EXPERT-C trial, HER2 does not appear to represent a useful therapeutic target in high-risk rectal cancer. However, the role of HER2 as a potential predictive biomarker of resistance to anti-EGFR-based treatments and a therapeutic target in anti-EGFR refractory metastatic colorectal cancer (CRC) warrants further investigation. Trial registration: ISRCTN Register: 99828560. Key words: HER2, rectal cancer, cetuximab, biomarker, neoadjuvant chemotherapy, chemoradiotherapy introduction HER2 is the second member of a family of transmembrane tyrosine kinase receptors involved in signal transduction pathways mediating tumour growth, differentiation and survival. Ligand independent homodimerisation or heterodimerisation occurs when HER2 is overexpressed with subsequent autophosphorylation of the intracellular tyrosine kinase domain and activation of the intracellular signalling cascade [1] .
HER2 is an oncogenic driver and a therapeutic target in breast and gastric cancers. HER2 overexpression and/or amplification were demonstrated to occur in up to 30% of breast cancers and be associated with aggressive tumour behaviour [2] . A similar percentage of oesophago-gastric cancers were found to overexpress HER2 [3] . In both diseases, adding trastuzumab, a monoclonal antibody targeting HER2, to standard chemotherapy has been shown to significantly improve response rates and survival in patients with HER2+ tumours [4, 5] .
Although HER2 overexpression has been reported in other malignancies, its role is less clear. In colorectal cancer (CRC), HER2 has been investigated with controversial results [6] [7] [8] [9] . Moreover, in most studies colon and rectal cancers (RCs) have been considered as a single entity and this prevented ascertaining the specific role of HER2 in either disease separately.
In this paper, we retrospectively analysed the prevalence and role of HER2 in high-risk, locally advanced RC patients treated with neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT)±cetuximab in a randomized phase II trial.
patients and methods patients
Eligibility criteria for the EXPERT-C trial have been described previously [10] . Briefly, patients had MRI-defined, high-risk rectal adenocarcinoma including tumours within 1 mm of mesorectal fascia, T3 tumour at/below levators, extramural extension ≥5 mm, T4 tumour or presence of extramural venous invasion.
Patients with available tumour tissue were eligible for this study. KRAS, NRAS, BRAF, PIK3CA mutations, PTEN status and EGFR copy number were analysed as part of the original translational substudy and the results reported previously [10] . A written informed consent was obtained from each patient.
procedures Trial procedures have been described previously [10] . Patients in both arms received CAPOX followed by CRT, total mesorectal excision (TME) and adjuvant CAPOX. Patients were randomly assigned to receive cetuximab with CAPOX and CRT or the control treatment. TME was carried out 4-6 weeks after completion of CRT. Adjuvant treatment consisted of four cycles of chemotherapy identical to the neoadjuvant phase. Patients were followed up for 5 years.
HER2 analysis
HER2 analysis was carried out in a centralized laboratory by a single pathologist blinded to the clinical data.
HER2 expression was determined by immunohistochemistry (IHC) using sections of formalin-fixed, paraffin-embedded tissue samples from pretreatment biopsies and/or surgical specimens. Slides of 2-3 µm were incubated in an oven for 40 min at 60°C for wax melting and subsequently placed on a fully automated VENTANA BENCHMARK® XT (Ventana, Tucson, AZ) IHC/ISH staining instrument.
The PATHWAY anti-HER2/neu rabbit monoclonal antibody (clone 4B5) (VENTANA Medical System Inc.) was used according to the protocol of the manufacturer. Immunostaining was scored according to the consensus panel recommendations on HER2 scoring for gastric cancer [11] . Scores 3+ were counted as positive, scores 0/1+ as negative. Tumours with equivocal result (2+) were tested for HER2 amplification by dual in situ hybridization (D-ISH) (supplementary Figure S1 , available at Annals of Oncology online).
The INFORM HER2 Dual ISH DNA Probe Cocktail assay (VENTANA Medical System XL TM) was used according to the protocol of the manufacturer. HER2 gene status was reported as a function of the ratio of the average number of HER2 gene copies to the average number of chromosome 17 centromere copies in nuclei of at least 30 tumour cells from each specimen. Cases with a HER2/CEP17 ratio of <1.8 were considered negative, whereas those with a ratio of >2.2 were considered positive. In the case of an equivocal result (ratio 1.8-2.2), additional 20 cancer cells were analysed and a ratio of ≥2.0 was used to define HER2 amplification.
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Following an initial low rate of HER2 expression, a repeat IHC test was carried out in a subgroup (10%) of randomly selected HER2− samples (score 0) to rule out a possible negative interference of pre-analytic factors and validate the IHC assay. For the same purpose, D-ISH was extended to all tumour samples scored 1+/3+ and a subgroup (15%) of randomly selected samples scored 0.
statistical analysis
The impact of HER2 on primary (complete response, CR) and secondary end points [R0 resection rate, progression-free survival (PFS) and overall survival (OS)] of the study was analysed [10] .
The rate of HER2 positivity was reported as proportion of subjects with 95% confidence intervals. When we planned this analysis, it was thought that HER2 was to be considered a clinically relevant biomarker if overexpression and/or amplification was ≥10%. If a detection rate of ≥10% was observed, the univariate association of HER2 with outcome measures would be assessed using binary logistic regression for CR and R0 resection rate and cox regression for survival end points.
results
Between 2005 and 2008, 165 patients were randomly assigned to CAPOX-cetuximab (n = 84) or CAPOX (n = 81) within the EXPERT-C trial. Of 164 eligible patients, 141 (86%) had tumour tissue available for analysis. Overall, 229 specimens were available. Of these, 218 were successfully analysed, of which 104 (63%) from pre-treatment biopsies (rate of successful HER2 assessment 94.5%) and 114 (69%) from surgical resections (rate of successful HER2 assessment 95.8%). The remaining samples were not analysed for the following reasons: tissue sample missing, insufficient tumour tissue, technical issues, absence of residual tumour due to pathologic CR, surgery omitted following radiologic CR or progressive disease (supplementary Figure S2 , available at Annals of Oncology online).
Patients eligible for this study were representative of the overall trial population (data not shown). Six out of 141 eligible patients (4.3%; 95%CI 1.8% to 9.2%) had a HER2+ tumour. Paired tumour specimens were available for 77 (55%) patients, including 3 with HER2+ tumours. Concordance for HER2 status was observed in 74 cases (96%, all with HER2− tumours), whereas the 3 patients with HER2+ tumours were found to have discordant results between biopsy and resection.
Overall, of 104 biopsies analysed with IHC, 99 (95.2%) were HER2− (97 scored 0, 2 scored 1+), 3 (2.9%) had an equivocal result and 2 (1.9%) were HER2+ (3+). Of 114 surgical specimens, 102 (89.5%) were HER2− (95 scored 0, 7 scored 1+), 11 (9.6%) had an equivocal result and 1 (0.9%) was HER2+ (3+) (supplementary Table S1 , available at Annals of Oncology online).
Fourteen specimens with equivocal IHC results were tested for HER2 amplification. Three cases (21.4%) were positive and nine (64.3%) were negative. In two cases, D-ISH failed due to technical issues. Overall, 3 of 104 (2.9%) biopsies and 3 of 114 (2.6%) surgical specimens were HER2+ (Table 1) .
When a repeat IHC test was carried out in 10% of randomly selected specimens scored 0, the results were fully concordant with the initial analysis. When the D-ISH analysis was extended to all tumour samples scored 1+/3+ and a subgroup of randomly selected samples scored 0, we observed that 2 of 32 samples scored 0 (6.2%, D-ISH score 2.04 and 3.05), 1 of 6 samples scored 1+ (16.7%, D-ISH score 2.92; 3 not assessable) and 1 of 2 samples scored 3+ (50%, D-ISH score 1.29 for the sample with no amplification; 1 not assessable) were found to be HER2 amplified. However, a repeat D-ISH analysis carried out on sequential tumour slides from three of these discordant cases (one not analysable) showed concordant results between IHC and D-ISH with no evidence of HER2 amplification in the absence of detectable HER2 expression.
HER2 positivity did not appear to be associated with any of the patient baseline clinical characteristics ( Table 2 ). As the HER2 positivity rate was <10%, no further univariate or multivariate analysis was undertaken.
Of the six HER2+ patients, two had received cetuximab in the experimental arm, whereas four were treated in the control arm. At the time of this analysis, the median follow-up was 58.6 months (95% CI: 57.8-60.2). Five HER2+ patients were alive and disease-free, whereas one, in the control arm, had died of tumour relapse. HER2 did not appear to be associated with a difference in the outcome for any of the study end points (Table 3) , including in the subset of KRAS/BRAF wild-type patients (data not shown).
discussion
In this study, we investigated the prevalence and role of HER2 in a homogeneous population of high-risk, locally advanced RC patients who had received a multimodality treatment including induction chemotherapy and CRT±cetuximab within a randomized phase II trial. We found that HER2 was overexpressed and/or amplified in a minority of patients. Moreover, HER2 did not appear to be associated with any specific clinico-pathological features, tumour genotypes or outcomes.
The identification of biomarkers predicting response to therapy and prognosis is of utmost importance in RC. After the standardization of TME, no further significant improvements have been made in the management of this disease. Although excellent rates of local tumour control have been obtained, a relevant number of patients still die of distant metastases. New therapeutic strategies have been explored with variable results [12] . In this scenario, the identification of biomarkers that could help select patients and implement individualized treatment strategies is of significant clinical relevance.
In locally advanced RC, HER2 does not appear to be a potentially useful biomarker. Although previous studies in CRC reported high rates of HER2 expression and the association of HER2 with advanced tumour stage and poor survival [6] , these results have not been subsequently confirmed. This inconsistency likely reflects the effect of several factors including the small sample size, the absence of homogeneity across study populations, the inter-individual variability in the evaluation of immunostaining and the use of different scoring systems [9] . When validated detection methods and accepted scoring systems were used, the rate of HER2 positivity was reported to be <8% [7, 9] . The first trial investigating trastuzumab in combination with irinotecan for advanced CRC was prematurely discontinued due to the low accrual related to the unexpectedly low rate of HER2 expression observed [8] .
Another trial investigating trastuzumab plus oxaliplatin-based chemotherapy in HER2+ chemorefractory metastatic CRC, had a similar unsuccessful outcome [13] . The rate of HER2 positivity we observed in the EXPERT-C trial is in line with most of the previous, similarly conducted studies and further contests the hypothesis of HER2 as a useful biomarker in resectable RC.
However, it is worth noting that in a recent analysis from the German Rectal Cancer Study Group, HER2 was found in 12.4% and 26.7% of pre-treatment biopsies and resection specimens, respectively [14] . More interestingly, in this study, HER2 positivity in surgical specimens was an independent predictor of cancer-specific survival. Although ethnicity was reported as a possible cause of differences in the frequency of HER2 expression [15] , it is unlikely that ethnicity alone could explain such strikingly diverging results. It is reasonable to hypothesize that other factors including the intratumoural heterogeneity of HER2 or the potential negative interference by pre-analytic factors in the HER2 analysis may have played a significant role.
HER2 heterogeneity has been reported in 5%-30% of breast cancer [16] . Studies have shown that this phenomenon is more common in gastrointestinal cancers, and may increase subjectivity in HER2 interpretation and lead to inaccurate assessment of HER2 status [11, 17] . This is especially true in locally advanced RC where the use of a multimodality strategy is associated with tumour necrosis and may limit significantly the availability of viable tumour tissue. Interestingly, 32% and 63% of patients who had undergone curative surgery in the EXPERT-C trial and in the pooled analysis of the German Rectal Cancer Study Group, respectively, had a tumour regression grade ≥3 after neoadjuvant treatment and for these patients the assessment of HER2 was based on the analysis of limited tissue from the baseline biopsies and/or the residual tumour at surgery [10, 14] . Indeed, consistent with the hypothesis of limited quantity and/or suboptimal quality of residual surgical tumour tissue, in two out of the three discordant cases observed in our study, the discrepancy between biopsy and surgery resulted from the absence of HER2 in resection specimens of patients found to be HER2+ at preoperative biopsy. Although we acknowledge the importance of tumour heterogeneity as a potential determinant of variability in the rate of HER2 positivity across studies, two important findings of our study are worth mentioning.
In patients with paired tumour specimens, a high consistency of HER2 status was observed (96%). This percentage compares favourably with the concordance rate in corresponding pairs of biopsies and resections previously reported [14] . The concordance rate between HER2 overexpression and HER2 amplification in our study was also high and consistent with that observed in breast cancer [18] , representing a further, indirect validation of the assays used for our analysis. In an exploratory analysis, only 7.9% of IHC-tumours were found to be D-ISH+. The interpretation of this phenomenon is still unclear as limited information is available on the significance of amplification of the HER2 gene in the absence of detectable HER2 expression [19] . Moreover, it is interesting to note that, when the analyses were repeated on sequential (rather than random) tumour slides from three of the four discordant cases, concordant results between IHC and D-ISH were observed.
Altogether, although potentially limited by the relatively small sample size, these two findings would minimize the likelihood that methodological issues (occurring in either the pre-analytic or analytic phase of the study) may have adversely affected the rate of HER2 positivity observed in our series. Moreover, the preliminary results of an exploratory ongoing analysis of HER2 mRNA expression on 132 tumour samples from the same study population are highly consistent with the IHC/D-ISH findings, with a high expression observed in only 4.5% of cases (data not shown).
Preclinical data suggest a potential involvement of HER2 in mediating resistance of RC to CRT [20] . Also, evidence has emerged that supports the involvement of HER2 in the mechanisms of resistance to cetuximab [21] and a potential role of anti-HER2 agents in restoring tumour sensitivity [22] . If further confirmed, these data could provide the rationale for future investigation of combined strategies with the upfront, or delayed until progression, use of anti-HER2 drugs in patients who are candidates of anti-EGFR therapies. Our series offered a unique chance to address the role of HER2 as a predictive factor of resistance to cetuximab-based CRT. Unfortunately, the small number of HER2+ tumours did not allow us to draw any conclusion on the association between HER2 expression and outcome.
In conclusion, based on the results of our analysis, HER2 does not appear to represent a useful biomarker and therapeutic target in locally advanced RC. Nevertheless, we believe that the potential role of HER2 as a predictor of acquired resistance to anti-EGFRs and potential therapeutic target in metastatic CRC warrants further investigation. Clinical trials investigating anti-HER2 agents in HER2+ CRC refractory to chemotherapy and anti-EGFRs are currently ongoing and will provide further insight into the role of HER2 in this setting.
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